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Context: Glucagon-like peptide-1 (GLP-1) is produced by specialized cells in the gut and secreted
in response to carbohydrates and lipids. The mechanisms regulating fat-stimulated GLP-1 release
have, however, not been clarified in detail.
Aim:We aimed to investigate the effect of intraduodenal (ID) fat hydrolysis on GLP-1 release and
test whether the signal is mediated through cholecystokinin (CCK)-1 receptors.
Design and Setting: Thirty-four healthy, male ambulatory volunteers were studied in three con-
secutive, randomized, double blind, crossover studies.
Intervention: Therewere three interventions: 1) 12 subjects receivedan ID fat infusionwithorwithout
orlistat, an irreversible inhibitor of gastrointestinal lipases, in comparison with vehicle; 2) 12 subjects re-
ceived ID sodium oleate (C18:1), ID sodium caprylate (C8:0), or ID vehicle; and 3) 10 subjects received ID
sodiumoleatewith andwithout the CCK-1 receptor antagonist dexloxiglumideor ID vehicle plus iv saline
(placebo). The effect of these treatments on GLP-1 concentrations and CCK releasewas quantified.
Results: The following results were reached: 1) ID fat induced significant increase in GLP-1 con-
centrations (P 0.004), and inhibition of fat hydrolysis by orlistat abolished this effect; 2) sodium
oleate significantly stimulatedGLP-1 release (P 0.008),whereas sodium caprylatewas ineffective
compared with controls; and 3) dexloxiglumide administration abolished the effect of sodium
oleate on GLP-1. ID fat or sodium oleate significantly stimulated plasma CCK (P  0.006 and P 
0.004) compared with saline, whereas sodium caprylate did not.
Conclusion: Generation of long-chain fatty acids through hydrolysis of fat is a critical step for
fat-induced stimulation of GLP-1 in humans; the signal is mediated via CCK release and CCK-1
receptors. (J Clin Endocrinol Metab 95: 879–886, 2010)
Glucagon-like peptide (GLP)-1 is an incretin hormonesecreted from enteroendocrine L cells that augment
insulin secretionafter oral intakeof ameal (1, 2).Themost
potent secretagogues for GLP-1 release are carbohydrates
and fat (3–5). Because iv glucose administration does not
induce secretion of GLP-1 (3), it appears that nutrients
within the lumen of the gut act on the luminal surface to
stimulate GLP-1 secretion.
The effects of fat on digestive functions and hormone
release are dependent on hydrolysis of triglycerides into
free fatty acids (6). For example, in healthy subjects, in-
hibition of fat digestion by the lipase inhibitor orlistat
attenuates the effects of duodenal triglyceride plasma cho-
lecystokinin (CCK) and GLP-1 concentrations (7, 8).
There is evidence that the gastrointestinal responses to fat
are also dependent on the chain length of intraluminal
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fatty acids. In humans, it has been reported that oleic acid
(C18:1), but notmedium-chain fatty acids (C8:0), reduces
energy intake (9), stimulates CCK and peptide YY (PYY)
release, and suppresses ghrelin secretion (10, 11). Gastro-
intestinal peptides, includingCCKandGLP-1,mediate, at
least in part, the effects of fat on energy intake (12) and
gastrointestinal motility (13, 14); hence, the role of fat
hydrolysis on gastrointestinal hormone secretion is clearly
of interest. Previous studies have shown that inhibition of
fat hydrolysis attenuates the release of GLP-1 (7, 8). Fur-
thermore, fatty acids with 12 carbons stimulated GLP-1,
whereas fatty acids with 10 carbons did not (15). Finally,
the generation of long-chain fatty acids through hydroly-
sis of fat was a critical step for fat-induced stimulation of
PYY in humans; the signal was in part mediated via CCK
release and CCK-1 receptors (11).
The aim of this study was therefore to investigate
whether CCKmediated the effect of intraduodenal fat on
GLP-1 secretion via CCK-1 receptors. Three major issues
relate to the present study: 1) the importance of adequate
fat digestion on plasma GLP-1 secretion; 2) the role of
fatty acid chain length in initiating the effects on GLP-1
secretion; and 3) the consequences of CCK-1 receptor
blockade on GLP-1 release.
Subjects and Methods
Subjects
Thirty-twomale subjects, aged 20–30 yr (mean 25.2 yr), par-
ticipated in the study. Body weight of all subjects was within the
normal range for age, sex, and height. Each subject gave written
informed consent for the study. The human ethics committee of
the University Hospital (Basel, Switzerland) approved the pro-
tocol. Before acceptance, each participant was required to com-
plete a medical interview, receive a full physical examination,
and participate in an initial laboratory screening.No subjectwas
receiving any medications or had a history of food allergies or
dietary restrictions.
Experimental procedures
Part I: effect of orlistat dissolved in olive oil on GLP-1
secretion
Three treatments, separated by at least 7 d, were performed
in 12 subjects in a randomized order. On the evening preceding
each treatment, subjects swallowed a radioopaque polyvinyl
feeding tube (external diameter 8French),whichhadopenings at
the tip of the tube. The tube was inserted through the nose be-
cause this procedure allowed the tube to be retained overnight
and for thedurationof the experiment.The tubewas transported
to the duodenum overnight. In the morning, the position of the
tube was located fluoroscopically, and the tip of the tube was
positioned100cmdistal to the teeth. Itwas firmly attached to the
skin behind the ear to prevent further progression of the tube
during the experiment.
The treatments were identical in design except for the in-
traduodenal infusions. One treatment consisted of intraduo-
denal vehicle infusion (see below) for the duration of the ex-
periment (120 min). In the second and third experiments,
intraduodenal fat (olive oil) with or without orlistat (30 mg/h)
was used instead of saline throughout the experiments. An in-
fusion rate of 0.5 ml/min oil was chosen for the duration of the
experiment; this rate was taken from previous experiments (6,
11). The intraduodenal fat infusion solution was indistinguish-
able in appearance from the control solution (vehicle). The treat-
ments were given in a double-blind manner. Blood samples (7.5
ml each)weredrawnat regular intervals intoEDTA-coated tubes
containing aprotinin (1000kIU/ml blood) for plasmaGLP-1 and
CCK determinations.
Part II: effect of free fatty acids (C8:0 andC18:1)GLP-1
release
Thedesign of the second serieswas similar to part I. The study
was conducted in a randomized, double-blind, and three-period
crossover fashion; 12 healthy male subjects participated in this
part. One treatment consisted of intraduodenal infusion of me-
dium-chain fatty acids. Medium-chain fatty acids in the form of
sodium caprylate, C8:0, were infused at a rate of 0.5 ml/min,
resulting in a load of 8 mmol/h sodium caprylate. In the second
experiment, long-chain fatty acids in the form of sodium oleate,
C18:1, were infused at a rate of 0.5ml/min, resulting in a load of
8 mmol/h. On the third experimental day, volunteers received
intraduodenal vehicle (control) instead of free fatty acids. The
sodium caprylate (C8:0) and sodium oleate (C18:1) loads were
chosen fromprevious experiments (11).During the experiments,
7.5-ml samples of blood were drawn into EDTA-coated tubes
containing aprotinin (1000kIU/ml blood) for plasmaGLP-1 and
CCK determinations.
Part III: effect of C18:1 with and without iv dexloxi-
glumide (DEXLOX) on GLP-1 secretion
The procedures in this series were similar to part II except for
the iv and intraduodenal infusions (sodium caprylate was not
infused in this part). Ten healthy male subjects participated in
this randomized, double-blind study. Subjects received on 2 ex-
perimental days a continuous intraduodenal infusion of sodium
oleate (C18:1; 8 mmol/h) together with either an iv infusion of
isotonic saline (control) or an infusion of the CCK-1 receptor
antagonist DEXLOX (5mg/kg  h) for the duration of the study.
The dose of DEXLOX was chosen from previous experiments
(11). Infusions were started 30 min before the intraduodenal
infusion. On the third experimental day, subjects received in-
traduodenal vehicle and iv saline for the duration of the study.
Infusions were delivered via ambulatory pumps through a cath-
eter inserted into a forearm vein. Blood was taken (7.5 ml sam-
ples) at regular intervals for GLP-1 and CCK determinations.
Drugs
Orlistat, also known as tetrahydrolipstatin (Xenical), was
purchased from Roche Ltd. (Basel, Switzerland). Orlistat is
poorly soluble in water; 120 mg orlistat was therefore dissolved
in a solution containing 140 ml distilled water with addition of
4 ml lecithin-ethanol solution plus 1.8 ml saccharose solution.
The lecithin-ethanol stock solution was made of 50 ml 96%
ethanol plus 0.75 g lecithin. The saccharose stock solution was
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prepared by adding 5 g saccharose to 10.0 ml distilled water;
themixturewas gently vortexed until the saccharosewas com-
pletely dissolved. An identical solution without orlistat was
used as a control solution. The sodium caprylate (C8:0) so-
lutionwas prepared as follows: 4.9 g of sodium caprylate were
dissolved in distilled water by gently stirring for 2 h; after
adding 1.2 ml 1 M hydrochloric acid, the solution was back-
titrated to pH 7.2 with addition of 1.2 ml 1 M NaOH. The
control solution was identical without adding sodium capry-
late. Finally, the following procedure was used to prepare the
sodium oleate (C18:1) solution: 8.6 g sodium oleate were
dissolved in 100 ml distilled water by gently stirring for 2 h;
the solution was stabilized at pH 9.5 by adding 1 M hydro-
chloric acid to titrate the pH to 9.5. All solutions were infused
to the small intestine at a rate of 30 ml/h.
DEXLOX, the (R)-isomer of loxiglumide, is a selective and
highly potent CCK1 receptor antagonist; the compound was
a kind gift of Dr. Lucio Rovati (Rotta Pharma SpA, Monza,
Italy).
Plasma hormone determinations
Plasma CCK concentrations were measured using a sensitive
RIA based on an antiserum that recognizes the sulfated tyrosine
residue of all CCK molecules but has little cross-reactivity with
sulfated gastrin (1%) and does not cross-react with unrelated
gastrointestinal peptides. Plasma samples were extracted with
ethanol. 125I-CCK-8 was used as a label. The lowest concentra-
tion that could be measured by the assay was 0.6 pmol/liter
plasmausingCCK-8as a standard.Details of the assayhavebeen
previously described (6, 11).
GLP-1 was measured with a commercially available ELISA
kit (Linco Research Inc., St. Charles, MO). This kit is for non-
radioactive quantification of biologically active forms of GLP-1
[i.e.GLP-1 (7-36 amide) and GLP-1 (7-37)] in plasma and other
biologicalmedia. It is highly specific for the immunologicalmea-
surement of active GLP-1 and will not detect other forms of
GLP-1 (e.g. 1-36 amide, 1-37, 9-36 amide, or 9-37). This assay
is based, sequentially, on the following: 1) capture of active
GLP-1 from sample by a monoclonal antibody, immobilized in
the wells of a microwell plate, that binds specifically to the N-
terminal region of active GLP-1 molecule, 2) washing to remove
unbound materials, 3) binding of an anti-GLP-1-alkaline phos-
phatase detection conjugate to the immobilizedGLP-1, 4) wash-
ing off unbound conjugate, and 5) quantification of bound de-
tection conjugate by adding methyl umbelliferyl phosphate,
which in the presence of alkaline phosphatase forms the fluo-
rescent product umbelliferone. Because the amount of fluores-
cence generated is directly proportional to the concentration of
activeGLP-1 in the unknown sample, the latter can be derived by
interpolation from a reference curve generated in the same assay
with reference standards of known concentrations of active
GLP-1. The intra- and interassay variability were less than 9 and
13%, respectively. The lowest level of GLP-1 that could be de-
tected by this assay was 0.25 pmol/liter when using a 100-l
plasma sample.
Statistical analysis
Results are presented as means SEM unless indicated oth-
erwise. Data were compared between the treatment groups by
ANOVA. If the ANOVA revealed significant differences, pair-
wise comparisons were performed by Tukey-honestly signif-
icant difference test. When data did not show a normal dis-
tribution, both tests were performed on log-transformed data.
All tests were performed as two-sided tests and the level of
significance was set to 0.05. All statistical comparisons were
performed using SPSS for Windows software (version 15.0;
SPSS, Chicago, IL).
Results
Part I
Fasting plasmaGLP-1 concentrations were similar in
the different treatments (Table 1). Fat infusion signifi-
cantly stimulated both GLP-1 and CCK secretions (Ta-
ble 1 and Fig. 1) compared with the control treatment
(infusion of vehicle to the duodenum). Orlistat (60 mg,
infused together with fat) reversed the effect of in-
traduodenal fat: the stimulation of GLP-1 release was
virtually blocked by the lipase inhibitor (P  0.001 fat
vs. fat plus orlistat).
TABLE 1. Pharmacodynamics of CCK and GLP-1 during intraduodenal infusions of fat or vehicle (control treatment)
with and without orlistat in 12 healthy male subjects
Treatments
ID vehicle (control) (A) ID fat alone (B) ID fat plus Orlistat (C)
CCK
Basal (pmol/liter) 0.8  0.1 0.9  0.1 0.9  0.1
AUC (0–120 min)
(pmol/min  liter)
115.4  4.18 (NA) 319.5  46.63 (P  0.001) 131.4  5.6 (NS)
Cmax (pmol/liter) 1.3  0.07 (NA) 3.9  0.63 (P  0.001) 1.4  0.11 (NS)
GLP-1
Basal (pmol/liter) 1.0  0.1 1.0  0.1 0.9  0.1
AUC (0–120 min)
(pmol/min  liter)
121.0  6.9 (NA) 356.9  16.9 (P  0.001) 120.4  6.7 (NS)
Cmax (pmol/liter) 1.3  0.1 (NA) 4.3  0.2 (P  0.001) 1.3  0.1 (NS)
Data are mean  SEM (n  12/group). P values represent statistically significant differences vs. control. ID, Intraduodenal; AUC, area under the
curve; Cmax, maximum concentration; NA, not applicable; NS, not significant.
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Part II
Fasting GLP-1 concentrations were comparable in the
different treatments (Table 2 and Fig. 2). During vehicle
infusion (control treatment) and infusion of sodium ca-
prylate (C8:0), plasma GLP-1 levels remained stable (Fig.
2). Intraduodenal administration of sodium oleate
(C18:1) caused a significant increase in both plasma
GLP-1 and CCK levels compared with controls (Table 2
and Fig. 2).
FIG. 1. Plasma concentrations of GLP-1 (A) and CCK (B), during
intraduodenal perfusions of triglycerides with or without the lipase
inhibitor orlistat (30 mg/h) or perfusion of vehicle (control treatment) in
12 healthy male subjects. Triglycerides perfused to the duodenum
induced a treatment  time interaction for GLP-1 and CCK (P  0.01
each). GLP-1 and CCK increased progressively during triglyceride
perfusion; inhibition of fat hydrolysis completely abolished these
effects: plasma GLP-1 and CCK concentrations were not different from
control values. Data are mean  SEM.
TABLE 2. Pharmacodynamics of CCK and GLP-1 during intraduodenal infusions of sodium oleate (C18:1), sodium
caprylate (C8:0), or infusion of vehicle (control treatment) in 12 healthy male subjects
Treatments
ID vehicle (control) (A) ID C8:0 (B) ID C18:1 (C)
CCK
AUC (0–120 min)
(pmol/min  liter)
114.2  5.2 (NA) 113.1  3.8 (NS) 272.3  23.1 (P  0.001)
Cmax (pmol/liter) 1.1  0.1 (NA) 1.2  0.1 (NS) 3.3  0.3 (P  0.001)
GLP-1
AUC (0–120 min)
(pmol/min  liter)
123.0  7.2 (NA) 136.2  7.2 (NS) 351.9  11.5 (P  0.001)
Cmax (pmol/liter) 1.3  0.1 (NA) 1.5  0.1 (P  0.072) 4.3  0.1 (P  0.001)
Data are mean  SEM (n  12/group). P values represent statistically significant differences vs. control. ID, Intraduodenal; AUC, area under the
curve; Cmax, maximum concentration; NA, not applicable; NS, not significant.
FIG. 2. Plasma concentrations of GLP-1 (A) and CCK (B) during
intraduodenal infusions of C18:1 (sodium oleate, 8 mmol/h), C8:0
(sodium caprylate, 8 mmol/h), or perfusion of vehicle (control
treatment) in 12 healthy male subjects. C18:1 increased GLP-1 and
CCK progressively compared with the control. C8:0 did not affect
hormone levels: plasma GLP-1 and CCK concentrations were not
different from control values. Data are mean  SEM.
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Part III
Similar to part II, intraduodenal infusion of sodium
oleate (C18:1) with iv infusion of saline caused a signifi-
cant increase in both GLP-1 and CCK levels. In contrast,
intraduodenal sodium oleate (C18:1) infusion together
with iv DEXLOX resulted in an attenuated GLP-1 re-
sponse compared with intraduodenal sodium oleate
(C18:1) plus iv saline (Table 3 and Fig. 3).
Finally, intraduodenal infusion of sodium oleate
(C18:1) with iv infusion of saline caused a significant in-
crease in plasmaCCK comparedwith controls (ID vehicle
plus iv saline). Intraduodenal sodium oleate (C18:1) in-
fusion together with iv DEXLOX resulted in a signifi-
cantly augmented CCK response (Table 3 and Fig. 3) in
comparison with ID sodium oleate (C18:1) plus iv saline
(P  0.004).
Discussion
Three different approaches were used to establish that fat
hydrolysis is a critical step in regulating GLP-1 secretion.
Fat digestion is required for the triggering of gastrointes-
tinal functions, such as gallbladder contraction and exo-
crine pancreatic secretion mediated by CCK release (6).
There is also evidence that the gastrointestinal re-
sponses to fat are also dependent on the chain length of
intraluminal fatty acids (5, 6, 8). Fatty acids with 12 or
more carbon atoms are transported from the gut pre-
dominantly in lymphatic chylomicrons, a transport pro-
cess that triggers a variety of gut signals including sa-
tiety and the slowing of gastric emptying (5). It has also
been reported that oleic acid (C18:1), but not C8:0,
reduces energy intake (12).
First, we used the lipase inhibitor orlistat as a tool to
determine whether inhibition of fat hydrolysis affects the
release pattern of GLP-1. Orlistat is known to inhibit fat
hydrolysis from a meal (or in the present study, the duo-
denal fat infusion) with subsequent effects on different
digestive functions (6–8). Stimulation of GLP-1 release in
response to fat in the small intestine was completely abol-
FIG. 3. Effect of DEXLOX, a specific CCK-1 receptor antagonist, on
plasma concentrations of GLP-1 (A) and CCK (B) during intraduodenal
infusion of sodium oleate (C18:1) or vehicle (control treatment) in 10
healthy male subjects. Sodium oleate (C18:1) increased GLP-1 and
CCK progressively compared with controls. Intravenous administration
of DEXLOX (5 mg/kg  h) attenuated the effects induced by sodium
oleate (C18:1): plasma GLP-1 concentrations were reduced by the
treatment. Data are mean  SEM.
TABLE 3. Pharmacodynamics of CCK and GLP-1 during ID infusions of sodium oleate (C18:1) or infusion of vehicle
(control treatment) with and without iv DEXLOX in 10 healthy male subjects
Treatments
ID vehicle plus iv saline
(control) (A)
ID C18:1 plus iv
saline (B)
ID C18:1 plus iv
DEXLOX (C)
CCK
AUC (0–120 min)
(pmol/min  liter)
164.0  12.5 (NA) 277.4  31.5 (NS) 1073.2  138.8 (P  0.001 vs. A) (P  0.001 vs. B)
Cmax (pmol/liter) 2.1  0.3 (NA) 3.5  0.4 (P  0.01) 14.7  1.5 (P  0.001 vs. A) (P  0.001 vs. B)
GLP-1
AUC (0–120 min)
(pmol/min  liter)
132.6  11.6 (NA) 356.8  17.3 (P  0.001) 175.8  7.0 (P  0.055)
Cmax (pmol/liter) 1.5  0.1 (NA) 4.0  0.2 (P  0.001) 2.2  0.1 (P  0.024)
Data are mean  SEM (n  10/group). P values represent statistically significant differences vs. the respective treatment (ANOVA, Tukey-honestly
significant difference test). ID, Intraduodenal; AUC, area under the curve; Cmax, maximum concentration; NA, not applicable; NS, not significant.
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ished by orlistat administration.We did not include a for-
mal control treatment (i.e. intraduodenal infusion of or-
listat in vehicle alone) in the present studybecausewehave
seen in previous investigations that orlistat alone does not
have any effect on the digestive system including hormone
release (6, 11). The data are in line with two recent studies
(8, 16): suppression of fat hydrolysis by orlistat inhibits
the release of GLP-1.
The critical importance of fat hydrolysis on digestive
functions is best illustrated by the products of fat digestion
on exocrine pancreatic secretory responses in animals and
humans: only duodenal infusion of long-chain free fatty
acids can stimulate maximal pancreatic enzyme and bi-
carbonate secretion, whereas undigested long chain tri-
glycerides are ineffective (17, 18). Inhibitionof lipolysis by
orlistat reduces the amount of free fatty acids in the small
intestine with a subsequent reduction in CCK release (6).
The reduction in CCK release prevents an adequate gall-
bladder contraction, results in a reduced postprandial
exocrine pancreatic secretory response, and induces an
attenuated inhibitory effect on further food intake (9, 12).
The results imply that the generation of long-chain free
fatty acids is a crucial step in the initiation of various di-
gestive processes.
In the second part of the study, we analyzed the impor-
tance of chain length of fatty acids in stimulating GLP-1
secretion. In this part, medium-chain fatty acids in the
formofC8:0or long-chain fatty acids in the formofC18:1
were infused into the small intestine. Sodium oleate
(C18:1) infusion resulted in a marked increase in GLP-1
concentrations,whereas sodiumcaprylate (C8:0) infusion
was ineffective. Feltrin et al. (15) previously evaluated the
effects of fatty acids of different chain lengths on GLP-1
secretion; fatty acids with 12 carbons but not fatty acids
with 10 carbons infusions increased plasma GLP-1 con-
centrations. These observations are in line with our
present results and suggest that in addition to fat hydro-
lysis, the chain length of free fatty acids is crucial for stim-
ulating GLP-1 secretion.
In the third part, we used the specific CCK-1 receptor
antagonist DEXLOX to block the actions of CCK: the
sodium oleate (C18:1)-stimulated GLP-1 response was
abolished with CCK-1 receptor blockade, suggesting that
the effect was, at least in part, mediated by CCK via its
CCK-1 receptor. We did not include a formal control
treatment (i.e. intraduodenal infusion of vehicle plus iv
infusion of DEXLOX) in the present study for two rea-
sons: 1) we have seen in previous investigations that
DEXLOX alone does not have any effect on gastrointes-
tinal hormone release in the fasting state (our unpublished
observations); 2) iv DEXLOX is no longer available for
human use and we had only limited amounts of drugs
available. In conclusion, the present results together with
previous observations document that adequate fat hydro-
lysis is required for stimulating GLP-1 release. The prod-
ucts of fat digestion stimulate CCK release, which in turn
regulates GLP-1 secretion via CCK-1 receptors.
GLP-1 secretion is initiated by either direct luminal
contact of nutrients with the endocrine cells and/or indi-
rectly through neurohumoral signals such as CCK (1, 2).
One potential pathway is a direct activation of CCK-1
receptors on afferent vagal fibers through sodium oleate
(C18:1) stimulation (19–23).One type of afferent fibers is
sensitive to long-chain fatty acids; furthermore, inhibition
of food intake induced by intraduodenal sodium oleate is
reversed by bilateral, subdiaphragmatic vagotomy or pre-
treatment with capsaicin (19–23). Because L cells are
more abundant in the distal part of the small intestine
(ileum) compared with the proximal part (duodenum and
proximal jejunum), it has been suggested that the early
rapid rise in GLP-1 after nutrient stimulation was not a
direct effect on the L cells but rather an indirect mediated
signal (proximal to distal model) (24). A second potential
pathway is therefore stimulation of GLP-1 secretion via
circulating CCK. The present study provides further evi-
dence for thismodel because blockade ofCCK-1 receptors
by a specific antagonist (DEXLOX) markedly reduced
fatty acid stimulated GLP-1 secretion.
This stimulatory pathway might be specific for fatty
acid-stimulated, but not glucose-stimulated, GLP-1 re-
lease because there is considerable experimental evidence
suggesting that luminal glucose can directly lead toGLP-1
secretion from the proximal gut: 1) although there are
more L cells in the distal gut than in the proximal part in
humans, there are enough cells in the proximal part to
stimulate GLP-1 release (25, 26); 2) the time course of
glucose-stimulated GLP-1 secretion (onset, peak, and du-
ration) is consistent with glucose-stimulating GLP-1 re-
lease from the proximal part, whereas the time course of
fatty acid stimulated GLP-1 release would suggest a stim-
ulation of GLP-1 over the entire small intestine (8, 24); 3)
infusion of small amounts of glucose to the duodenum
stimulates GLP-1 release in healthy subjects (13); and fi-
nally 4) studies with isolated tissues from wild-type and
a-gust/mice suggest that direct sensing of glucose in the
proximal part of the gut stimulates GLP-1 release from
proximal L cells (27, 28); unfortunately, similar studies
have not been performed with fatty acids.
The present and previous observations have physiolog-
ical implications: they suggest a mechanism through
which CCK plays a role in regulating food intake and
appetitewith fat hydrolysis and the generationof free fatty
acids as triggers to further stimulate GLP-1 and PYY or
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both. These peptides in turn inhibit further food intake
and decrease appetite.
The plasma CCK levels were markedly higher with
DEXLOXcomparedwith the control treatment.This phe-
nomenon has been observed before with CCK-1 receptors
(29, 30): the explanations include activation of a negative
feedback mechanism due to low concentrations of bile
and/orpancreatic juice constituents in theduodenal lumen
and interference with autoregulatory, inhibitory CCK-1
receptors on the I cell.
In summary, the three major issues that relate to the
present study are: 1) the importance of adequate fat di-
gestion on plasma GLP-1 secretion; 2); the role of fatty
acid chain length in initiating the effects on GLP-1 secre-
tion, and 3) the consequences ofCCK-1 receptor blockade
onGLP-1 release. Thedata support the following concept:
fat hydrolysis in the proximal small intestine plays a cru-
cial regulatory function for digestive processes; adequate
fat hydrolysis is required to start the process; the specific
products of fat digestion, long-chain fatty acids, then stim-
ulate the release of CCK; CCK in turn acts on CCK-1
receptors,which then initiate a series ofdigestive functions
including modulation of GLP-1 secretion.
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